Clinical trial
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
NCT00474812 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00474812 |
|---|---|
| Title | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug, Procedure |
| Interventions | dasatinib, laboratory biomarker analysis, physiologic testing |
| Enrollment | 51 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Feb 1, 2014 |
| First posted | May 17, 2007 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: